JP Morgan Healthcare Conference J anuary 12, 2026 Safe harbor and non-GAAP disclosures Certain statements in this presentation and the accompanying oral commentary are forward-looking statements within the meaning of federal securities laws. These statements relate to future events or Guardant Health, Inc. (the "Company")'s future results and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or i ...

Financial Results - Guardant Health, Inc. announced preliminary unaudited financial information for Q4 and full year 2025 on January 11, 2026[4]. - The press release containing financial results is filed as Exhibit 99.1[7]. Upcoming Events - The company will present at the 2026 J.P. Morgan Healthcare Conference on January 12, 2026, with details available on their website[5].

Qiagen FY Conference Summary Company Overview - **Company**: Qiagen (NYSE: QGEN) - **Industry**: Life Sciences Tools and Diagnostics - **Market Position**: Qiagen has been developing molecular solutions for over 40 years, focusing on PCR, digital PCR, and next-generation sequencing, serving over 500,000 customers globally with a revenue of $2 billion, primarily from recurring consumables [3][4] Core Business Highlights - **Balanced Revenue Sources**: Over 50% of revenues come from the Americas, with significant contributions from Europe, the Middle East, Africa, and emerging markets [4] - **Growth Strategy**: Qiagen aims for a 7% CAGR through 2028, targeting $2 billion in revenues from key growth pillars and maintaining a 31% EBIT margin [6][7] - **Shareholder Returns**: Commitment to return at least $1 billion to shareholders, with recent share buybacks totaling $500 million [8][21] Financial Performance and Guidance - **2025 Performance**: Anticipated core growth of 5%-6% and EPS of $2.38, with operational execution on track [9] - **2026 Outlook**: Expected revenue growth of 5%-7%, with Parse Biosciences contributing approximately $40 million [24] Product Development and Innovations - **Sample Technology Leadership**: Qiagen is focusing on enhancing sample technology, with new instruments like QIAsymphony Connect and QIAmini set to launch [15][16] - **Digital PCR Growth**: The digital PCR market is expected to grow at 15%-20%, with Qiagen leading in placements and offering unique companion diagnostic solutions [25][26] - **QuantiFERON and Syndromic Testing**: QuantiFERON continues to show double-digit growth, with a target of $600 million in revenues by 2028. QIAstat is positioned as a solid number two in syndromic testing, with a target of $200 million by 2028 [10][31][32] Market Dynamics and Competitive Landscape - **Digital PCR Market**: Qiagen is competing with established players like Bio-Rad and Thermo Fisher, with a focus on expanding its assay offerings [25][26] - **QuantiFERON Competition**: Qiagen maintains a competitive edge through continuous investment in technology and partnerships, despite the presence of competitors [30] - **Syndromic Testing Market**: QIAstat is expected to grow with new panel approvals and a strong installed base, targeting unmet medical needs [31][32] Research and Development Focus - **Investment in R&D**: Qiagen allocates 9%-10% of revenues to R&D, focusing on automation and high-value applications [11][14] - **AI Integration**: The company is leveraging AI across various dimensions, including sales, marketing, and manufacturing, to enhance operational efficiency [19][20] M&A Strategy - **Acquisition Criteria**: Qiagen focuses on bolt-on acquisitions that are synergistic, immediately accretive to sales, and financially beneficial within two to three years [18][40] - **Recent Acquisitions**: The acquisition of Parse Biosciences and Genoox enhances Qiagen's capabilities in sample technology and bioinformatics [18][19] Conclusion - **Future Outlook**: Qiagen is optimistic about market recovery in the second half of 2026, continued growth in digital PCR, and the impact of new product launches in sample technology [41][42]

Core Insights - Guardant Health reported a breakout year in 2025, with total revenue growth accelerating to 33% year-over-year, driven by innovation in its Smart Platform and strong commercial execution [2][5] - The company highlighted the success of its Shield product in the blood-based colorectal cancer screening market, with nearly 100,000 patients screened since FDA approval [2][5] - Guardant Health plans to launch multiple groundbreaking products in 2026 to sustain growth momentum in its Oncology business [2] Financial Performance - For Q4 2025, total revenue was approximately $280 million, an increase of 39% compared to Q4 2024 [5] - The company reported approximately 79,000 oncology tests in Q4 2025, a 38% increase year-over-year [5] - For the full year 2025, total revenue reached approximately $981 million, reflecting a 33% increase from 2024 [5] - The number of oncology tests conducted in 2025 was approximately 276,000, marking a 34% increase [5] - Shield screening tests totaled approximately 87,000 in 2025, up from 6,400 in the prior year [5] Cash Flow and Financial Position - Preliminary unaudited free cash flow was approximately negative $54 million for Q4 2025 and approximately negative $233 million for the full year 2025 [2] - As of December 31, 2025, the company had approximately $1.3 billion in cash, cash equivalents, restricted cash, and marketable debt securities [2]

Core Insights - Artificial intelligence (AI) is identified as the greatest investment opportunity of the current era, with a strong emphasis on the urgency to invest now [1][13] - The energy demands of AI technologies are significant, with data centers consuming as much energy as small cities, leading to concerns about power grid strain and rising electricity prices [2][3] Investment Opportunity - A specific company is highlighted as a critical player in the AI energy sector, owning essential energy infrastructure assets that are poised to benefit from the increasing energy demands of AI [3][7] - This company is not a chipmaker or cloud platform but is positioned as a "toll booth" operator in the AI energy boom, collecting fees from energy exports [5][6] Financial Position - The company is noted for being debt-free and holding a substantial cash reserve, amounting to nearly one-third of its market capitalization, which provides a strong financial foundation [8][10] - It is trading at less than 7 times earnings, making it an attractive investment compared to other firms in the energy and utility sectors [10][12] Market Trends - The company is strategically aligned with several market trends, including the onshoring boom driven by tariffs, a surge in U.S. LNG exports, and a focus on nuclear energy as a clean power source [14][7] - The influx of talent into the AI sector is expected to drive continuous innovation and advancements, further solidifying the importance of investing in AI-related companies [12][11] Future Outlook - The potential for significant returns is emphasized, with projections suggesting a possible 100% return within 12 to 24 months for investors who act quickly [15][19] - The overall narrative suggests that AI is a disruptive force that will reshape traditional industries, and companies that adapt will thrive [11][12]

*Real-time prices by Nasdaq Last Sale. Real-time quote and/or trade prices are not sourced from all markets. Ownership data provided by LSEG and Estimate data provided by FactSet. IBD, IBD Digital, IBD Live, IBD Weekly, Investor's Business Daily, Leaderboard, MarketDiem, MarketSurge and other marks are trademarks owned by Investor's Business Daily, LLC. ©2026 Investor's Business Daily, LLC. All Rights Reserved. Terms of Use Privacy Notice Accessibility About Us Reviews Site Map Your Ad Choices Advertising C ...

Core Insights - Guardant Health, Inc. announced that its Shield blood test for colorectal cancer screening is now covered for active-duty service members and their families through TRICARE, with no copay for average-risk individuals aged 45 and older [1] Company Overview - Guardant Health is a leading precision oncology company focused on innovative cancer screening solutions [1] Product Details - The Shield blood test is the first and only blood test approved by the FDA as a primary screening option for colorectal cancer [1]

Core Insights - Insight Molecular Diagnostics Inc. has appointed Dr. Nick Ioannou as Vice President of Medical Affairs, bringing extensive experience in organ transplant, nephrology, cardiology, genetics, and oncology [1][5] Company Overview - Insight Molecular Diagnostics is a pioneering diagnostics technology company focused on democratizing access to novel molecular diagnostic testing to improve patient outcomes [6] Dr. Nick Ioannou's Background - Dr. Ioannou has over three decades of experience in clinical practice, diagnostics, regulatory affairs, medical education, and medical affairs, with significant collaboration with key opinion leaders in various therapeutic areas [2] - His previous roles include senior positions at Guardant Health, Natera, LA Ort Institute, L-Nutra, and CSL Behring, among others [3] - He has nearly 10 years of experience as a medical director and partner in private clinics, enhancing his ability to connect with patients and healthcare professionals [4] Strategic Importance of Appointment - The CEO of iMDx, Josh Riggs, emphasized that Dr. Ioannou's expertise is crucial for the company as it prepares to launch its first commercial products in transplant rejection testing [5] - Dr. Ioannou expressed enthusiasm about joining iMDx, highlighting the need for improved transplant rejection testing paradigms [5]

Group 1: Market Outlook - Scott Wren, chief global equity strategist at Wells Fargo Investment Institute, expressed optimism about accelerating earnings and moderating inflation, projecting a 2.8% CPI target for the next year [1] - Wren characterized the combination of modest growth and moderating inflation as favorable for risk assets in the upcoming year [1] Group 2: Investment Strategy - The firm has utilized broad risk additions and internal sector rotations, shifting away from heavy concentrations in technology while maintaining a preference for US markets over international ones [2] - Wren indicated a neutral stance on developed international and emerging markets, favoring large-cap and mid-cap stocks [2] Group 3: Stock Performance and Analyst Ratings - Robinhood Markets Inc. (NASDAQ:HOOD) has a market capitalization of $105.52 billion and a year-to-date performance of 215.83% as of December 29, with 77 hedge fund holders [7] - Needham lowered its price target for Robinhood to $135 from $145, citing a prolonged slump in cryptocurrency trading volume [8] - Morgan Stanley raised its price target for Robinhood to $147 from $146, increasing Q4 EPS estimates by an average of 5% [9] - Barclays also increased its price target for Robinhood to $171 from $168, maintaining an Overweight rating [10] Group 4: Guardant Health Inc. Overview - Guardant Health Inc. (NASDAQ:GH) has a market capitalization of $13.18 billion and a year-to-date performance of 233.29% as of December 29, with 50 hedge fund holders [12] - Canaccord raised its price target for Guardant Health to $125 from $100, expecting the life science sector to maintain an upward trend into 2026 [12] - Mizuho and Bank of America also raised their price targets for Guardant Health to $120 from $100, maintaining positive ratings based on anticipated growth in the life sciences sector [13][14]

Core Insights - Artificial intelligence (AI) is identified as the greatest investment opportunity of the current era, with a strong emphasis on the urgent need for energy to support its growth [1][2][3] Investment Opportunity - A specific company is highlighted as a potential investment opportunity, possessing critical energy infrastructure assets that are essential for meeting the increasing energy demands of AI data centers [3][7] - This company is not a chipmaker or cloud platform but is positioned to benefit significantly from the anticipated surge in electricity demand driven by AI technologies [3][6] Energy Demand and Infrastructure - AI technologies, particularly large language models like ChatGPT, are extremely energy-intensive, with data centers consuming as much energy as small cities [2] - The company in focus is involved in the U.S. LNG exportation sector, which is expected to grow under the current administration's energy policies [7] Financial Position - The company is noted for being debt-free and holding a substantial cash reserve, amounting to nearly one-third of its market capitalization, which positions it favorably compared to other energy firms burdened with debt [8] - It is trading at less than 7 times earnings, indicating a potentially undervalued investment opportunity in the context of its critical role in the AI and energy sectors [10] Market Trends - The article discusses the broader trends of onshoring and tariffs that are influencing the energy and manufacturing sectors, suggesting that this company is well-positioned to capitalize on these trends [5][14] - The influx of talent into the AI sector is expected to drive continuous innovation and advancements, further solidifying the importance of energy infrastructure in supporting this growth [12] Conclusion - The company is described as a "toll booth" operator in the AI energy boom, collecting fees from energy exports and benefiting from the increasing demand for electricity in the digital age [4][5] - The overall message emphasizes the urgency for investors to act now to capitalize on the potential returns associated with AI and energy investments [13][15]